¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"complement fixation inhibition test"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • biuret test
    ºä·¿°Ë»ç
  • blank test
    ºí·©Å©Å×½ºÆ®, °ø½ÃÇè, ´ëÁ¶½ÃÇè
  • bleeding time test
    ÃâÇ÷½Ã°£°Ë»ç
  • blood coagulation test
    Ç÷¾×ÀÀ°í°Ë»ç
  • blood sugar test
    Ç÷´ç°Ë»ç
  • blood test
    Ç÷¾×°Ë»ç
  • bone conduction test
    »ÀÀüµµ°Ë»ç, °ñÀüµµ°Ë»ç
  • balloon occlusion test
    dz¼±Æó¼â°Ë»ç
  • breath holding test
    ¼ûÂü±â°Ë»ç, È£ÈíÁßÁö°Ë»ç
  • bronchial challenge test
    ±â°üÁöÀ¯¹ß°Ë»ç
  • clearance test
    û¼ÒÀ²½ÃÇè
  • clock-drawing test
    ½Ã°è±×¸®±â°Ë»ç
  • cold pressure test
    ÇÑ·©¾Ð¹Ú°Ë»ç
  • contraction stress test
    ¼öÃàÀڱذ˻ç
  • Coombs¡¯ test
    ÄñÁî°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • articulation test
    ¹ßÀ½°Ë»ç
  • artificial erection test
    Àΰø¹ß±â°Ë»ç
  • audibility test
    û·Â°Ë»ç, û·ÂÃøÁ¤
  • auditory recruitment test
    û°¢º¸Ãæ°Ë»ç
  • autoclave test sheet
    ¸ê±ÕÈ®Àΰ˻çÁö
  • autohemolysis test
    ÀÚ°¡¿ëÇ÷½ÃÇè
  • bactericidal test
    »ì±Õ½ÃÇè
  • bacteriophage neutralization test
    ¹ÚÅ׸®¿ÀÆÄÁöÁßÈ­½ÃÇè
  • balloon occlusion test
    dz¼±Æó¼â°Ë»ç
  • basic secretion test
    ±âº»ºÐºñ°Ë»ç
  • basophil degranulation test
    È£¿°±â±¸Å»°ú¸³°Ë»ç
  • bead test
    ±¸½½½ÃÇè, ±¸½½°Ë»ç
  • bile solubility test
    ´ãÁó¿ëÇØµµ°Ë»ç
  • biliary drainage test
    ´ãÁó¹èÃâ°Ë»ç, ´ãÁó¹è¾×°Ë»ç
  • biological test
    »ý¹°ÇÐÀû½ÃÇè
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • Dick test
    µñÅ©½ÃÇè
  • Dick test
    µñ °Ë»ç
  • Donath-Landsteiner test
    µµ³ª¾²¶õÆ®½ºÅ¸ÀÌ³Ê °Ë»ç
  • Draw-A-Person test(DAP)
    Àι°È­°Ë»ç
  • Du test
    Du °Ë»ç (ÁÖÀÇ : u ´Â À­Ã·ÀÚÀÓ)
  • Eleks gel-precipitin test
    ¿¤·ºÅ©ÇÑõÆòÆÇħ°­¹ý (µðÇÁÅ׸®¾Æµ¶¼Ò µ¿Á¤¹ý)
  • Falcon assay screening test
    ÆÈÄܺм®¼±º°½ÃÇè
  • Farnworth D-15 test
    ÆÄ¸¥¿ö½º15»ö»ó°Ë»ç
  • Farnworth-Munsell 100 hue test
    ÆÄ¸¥¿ö½º-¹®¼¿ 100»ö»ó°Ë»ç
  • Freda test
    ÇÁ·¹´Ù½ÃÇè
  • Frei s test
    ÇÁ¶óÀ̽ÃÇè<¹ÝÀÀ>
  • Frei test
    ÇÁ¶óÀ̽ÃÇè
  • Freis test
    ÇÁ¶óÀ̰˻ç
  • Friedman test
    ÇÁ¸®µå¸¸½ÃÇè
  • Frye test
    ÇÁ¶óÀ̽ÃÇè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • fixation forceps
    ¾È±¸°íÁ¤°âÀÚ.
  • fixation forceps
    °íÁ¤Áý°Ô
  • fixation light
    Áֽõî
  • fixation line
    Áֽü±
  • fixation movement
    Áֽÿ(ãÊê¡ÔÑ).
  • fixation muscle =fixing m.
    °íÁ¤±Ù.
  • fixation nystagmus
    ÁֽþÈÁø(ñ¼ãÊäÑòè).
  • fixation nystagmus
    °í½Ã¾ÈÁø
  • fixation object
    Áֽù°Ã¼
  • fixation point
    ÁÖ½ÃÁ¡(ñ¼ãÊïÇ)
  • fixation reflex
    Áֽùݻç
  • fixation, nitrogen
    Áú¼Ò°íÁ¤
  • following fixation
    ÃßÁ¾ÁÖ½Ã
  • intermaxillary fixation
    ¾Ç°£°íÁ¤.
  • intramaxillary fixation
    ¾Ç°£°íÁ¤.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • metyrapone test
    ¸ÞƼ¶óÆù°Ë»ç(ËþÞÛ)
  • Molisch test
    ¸ô¸®½¬ ½ÃÇè(ãËúÐ)
  • Morner's test
    ¸ð³Ê ½ÃÇè(ãËúÐ)
  • murexide test
    ¹Â·¡½Ãµå°Ë»ç(ËþÞÛ)
  • patch test
    ÆÐÄ¡½ÃÇè(ãËúÐ)
  • phase test
    »ó½ÃÇè(ßÓãËúÐ)
  • phenolsulfonphthalein test
    Æä³î¼³ÆùÅ»·¹ÀÎ ½ÃÇè(ãËúÐ)
  • phenylalanine load test
    Æä´Ò¾Ë¶ó´Ñ ºÎÇϽÃÇè(ݶùÃãËúÐ)
  • phenylalanine tolerance test
    Æä´Ò¾Ë¶ó´Ñ ³»¼º½ÃÇè(Ò±àõãËúÐ)
  • PSP test
    (å²) Phenolsulfonphthalein test
  • radioactive antibody test
    ¹æ»ç¼º Ç×ü ½ÃÇè(°ËÁ¤)(Û¯ÞÒàõù÷ô÷ãËúÐ(ËþïÒ))
  • resorcinol test
    ¸®Á¶¸£½Ã³î ½ÃÇè(ãËúÐ)
  • reversible boundary spreading test
    °¡¿ª °æ°è ºÐ»ê ½ÃÇè(ʦæ½ÌÑÍ£ÝÂߤãËúÐ)
  • Rice test
    ¶óÀ̽º ½ÃÇè(ãËúÐ)
  • ring test
    °í¸®½ÃÇè(ãËúÐ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
FFIT fluorescent focus inhibition test
HIMT hemagglutination inhibition morphine test
LAIT latex agglutination inhibition test
RFFIT rapid fluorescent focus inhibition test
ASIF Association for Study of Internal Fixation
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
CR3 Complement receptor type 3
CR1 Complement receptor type one
CAMC Complement-dependent antibody-mediated cytotoxicity
EAC Erythrocyte antibody complement
RCA Regulator of complement activation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • binaural distorted speech test
    ¾çÀÌ¿ÖÈ­ ½ÃÇè
  • Binet's test
    ºñ³× ½ÃÇè
    ¼Ò¾Æ¿Í û³âÀÇ Á¤½Å ´É·ÂÀ» °Ë»çÇÏ´Â ¹æ¹ýÀ¸·Î, °¢Á¾ ¿¬·É¿¡¼­ÀÇ Á¤»ó ¾Æµ¿ÀÇ ´É·Â¿¡ ÀûÇÕÇϰí Ç¥ÁØÈ­µÈ ÀÏ·ÃÀÇ Áú¹®À» ÇǰËÀÚ¿¡°Ô ÇÏ¿©, ÀÌ¿¡ ´ëÇÑ ´ë´ä¿¡ µû¶ó ÇǰËÀÚÀÇ Á¤½Å ¿¬·ÉÀ» °áÁ¤ÇÏ´Â °Í.
  • Bing test
    ºù ½ÃÇè
    Áøµ¿À½Â÷¸¦ À¯¾çµ¹±â À§¿¡ ³õ°í, ûµµ¸¦ ±³´ë·Î Æó¼âÇÏ¿´´Ù°¡ °³¹æÇÏ¿´´Ù°¡ ÇÑ´Ù. ¼Ò¸®ÀÇ ³ô°í ³·À½Àº Á¤»ó ±Í¿¡¼­ ûÃëµÇ¸ç, ¶ÇÇÑ Áö°¢½Å°æ¼º û°¢½Å°æ¼º û°¢Àå¾Ö¿¡¼­µµ µé¸®³ª, Àüµµ û°¢ Àå¾Ö¿¡¼­´Â ¼Ò¸®ÀÇ Â÷À̰¡ ¾øÀÌ µé¸°´Ù.
  • biuret test
    ¹ÙÀÌÀ¯·¿ ½ÃÇè
  • blank test
    °ø½ÃÇè
  • bleeding time test
    ÃâÇ÷ ½Ã°£ ½ÃÇè
  • blood sugar test
    Ç÷´ç °Ë»ç
  • blood test
    Ç÷¾× °Ë»ç, Ç÷¾× °Ë»ç¹ý
    Áúº´ÀÇ Áø´Ü, Ä¡·á ¹× ¿¹ÈÄ ÆÇÁ¤À» ¸ñÀûÀ¸·Î Ç÷¾×ÀÇ °¢Á¾ ¼ººÐÀ» °Ë»çÇÏ´Â ÀÏ. ¸ö ÀüüÀÇ Àå±â³ª Á¶Á÷¿¡ º´º¯ÀÌ ÀÖÀ¸¸é ÀÌµé ¼ººÐ¿¡ º¯È­°¡ ÀÖ°Ô µÇ¾î Áø´Ü¿¡ Å« µµ¿òÀ» ÁØ´Ù. ©ç ÇüÅÂÇÐÀû °Ë»ç¹ý : Ç÷¾×ÀÇ ¼¼Æ÷ÇÐÀû ¹× ÀÌÇÐÀûÀÎ ¼ºÁú°ú »óŸ¦ °Ë»çÇÏ´Â °ÍÀ¸·Î¼­ äÇ÷ÇÏ¿© ÀûÇ÷±¸ ¼ö, Ç÷»ö¼Ò·®, ÀûÇ÷±¸ ¿ëÀû°ú À̵鿡¼­ °è»êµÇ´Â °è¼ö¿Í ¹éÇ÷±¸ ¼ö, Ç÷¼ÒÆÇ ¼ö, ¸Á»ó ÀûÇ÷±¸ ¼ö µîÀ» °Ë»çÇÏ°í ¶Ç Ç÷¾× ÇÑ ¹æ¿ïÀ» ½½¶óÀÌµå ±Û¶ó½º¿¡ ¾ã°Ô ¹Ù¸¥ °ÍÀ» ¿°»öÇÏ¿© ¹éÇ÷±¸ÀÇ Á¾·ù, °¢Á¾ Ç÷±¸ÀÇ ÁúÀû º¯È­¸¦ Á¶»çÇÑ´Ù. ¶Ç ÃâÇ÷ ½Ã°£, ÀÀ°í ½Ã°£, ¸ð¼¼Ç÷°ü ÀúÇ× µîÀ» °Ë»çÇØ¼­ ÃâÇ÷ °æÇâ, Ç÷¾× Áúȯ, °¨¿°Áõ µîÀÇ Áø´Ü°ú °¢Á¾ ÁúȯÀÇ °æ°ú¿Í ¿¹ÈÄ ÆÇÁ¤¿¡ Å« µµ¿òÀÌ µÈ´Ù. ©è »ýÈ­ÇÐÀû °Ë»ç¹ý : Ç÷¾× ¼ÓÀÇ ¿©·¯ ¼ººÐÀ» »ýÈ­ÇÐÀû ¹æ¹ýÀ¸·Î ÃøÁ¤ÇÏ´Â °ÍÀ¸·Î Ç÷û ´Ü¹éÁú
  • bone conduction test
    °ñÀüµµ ½ÃÇè
  • Bonsignore test
    º»½Ã±×³ë ½ÃÇè
  • bracelet test
    ¿Ï·û ½ÃÇè
  • breakdown test
    ÆÄ±« ½ÃÇè
  • breath holding test
    È£Èí ÁßÁö ½ÃÇè
  • Brucellosis test
    ºê·ç¼¿¶óÁõ ½ÃÇè
  • butyric acid test
    ³«»ê ½ÃÇè
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
complement 3d <chemical> An inactivated fragment of complement 3b (c3b). Factor h makes c3b susceptible to factor I (formerly called kaf, c3binf, or enzyme 3b inactivator) to form ic3b. Then factor I and a trypsin-like proteolytic enzyme further cleave ic3b into c3c and c3dg. Serum proteases degrade c3dg into complement 3d (c3d) and c3g.
Chemical name: Complement C3d
(12 Dec 1998)
complement 3 nephritic factor A magnesium-dependent IgG autoantibody found in serum of patients with chronic mesangioproliferative hypocomplementemic glomerulonephritis. It causes inactivation of c3 in the alternate pathway by cleaving c3 into two inactive fragments, c3c and c3d, instead of the normal c3b.
(12 Dec 1998)
complement 4 The second component to react in the complement sequence. It is a beta-globulin with a sedimentation coefficient of 18.7, a molecular weight of 240,000 and a serum concentration of 430 micrograms/ml. It is activated by complement 1 and serves as a receptor for c2.
(12 Dec 1998)
complement 4a <chemical> Smaller fragment formed when c1s splits c4 into c4a and c4b. As an anaphylatoxin, c4a causes symptoms of immediate hypersensitivity but it has weaker activity than c3a or c5a.
Chemical name: Complement C4a
(12 Dec 1998)
complement 4b <chemical> Larger fragment formed when c1s splits c4 into c4a and c4b. C4b combines with c2b to form the activated c4b2b complex which is often called the classical pathway c3 convertase.
Chemical name: Complement C4b
(12 Dec 1998)
complement 5 The fifth component in the complement reaction sequence, probably exists in a complex with c6 and c7. It is a beta-globulin with a sedimentation coefficient of 10, serum concentration of 75 micrograms/ml and molecular weight of 180,000. It is activated by c423 and releases fragments with anaphylatoxic, chemotactic, and histamine-releasing actions and affecting smooth muscle.
(12 Dec 1998)
complement 5a <chemical> Smaller fragment formed when c5 convertase splits c5 into c5a and c5b. C5a is a 74-amino acid peptide that includes a carboxy-terminal arginine crucial for its spasmogenic activity and a carbohydrate moiety. C5a is the most potent anaphylatoxin mediating immediate hypersensitivity.
Chemical name: Complement C5a
(12 Dec 1998)
complement 5a, des-arginine Complement 5a with the carboxy-terminal arginine removed. The arginine is rapidly cleaved from the c5a fragment during complement activation by carboxypeptidase b present in normal human serum. C5a des-arg shows complete loss of spasmogenic activity though it retains some chemotactic ability.
(12 Dec 1998)
complement 6 The sixth component in the complement reaction sequence. It is a beta-globulin with a sedimentation coefficient of 8.7 and a molecular weight of 120,000 at 60 micrograms/ml in serum. It may exist in a complex with c5 and c7 and is activated by the binding of c5.
(12 Dec 1998)
complement 7 The seventh component in the complement reaction sequence. It is a beta-globulin probably in a complex with c5 and c6 and is activated by c5. The attachment of c7 renders the cell susceptible to lysis.
(12 Dec 1998)
complement 8 The next to the last essential component for cell lysis in the complement reaction sequence. It is a gamma-globulin with a molecular weight of 150,000 and a sedimentation coefficient of 8. It is present in trace amounts in serum and can be inhibited, like complement 1, by cation chelators.
(12 Dec 1998)
complement 9 The last component in the complement reaction sequence. It is an alpha-globulin present in serum as a trace, with a molecular weight of 80,000 and a sedimentation coefficient of 4.5. For cell lysis, it can be replaced by a metal chelator.
(12 Dec 1998)
complement activating enzymes <enzyme> Enzymes present in the complement system which activate one or more components in the system.
Registry number: EC 3.-
(12 Dec 1998)
complement activation The sequential activation of serum components c1 through c9, initiated by an erythrocyte-antibody complex or by microbial polysaccharides and properdin, and producing an inflammatory response.
(12 Dec 1998)
complement binding assay A test for the detection of immune complexes.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á